The Valley Desk

NCT03744468 · Interventional trial

Study of Surzebiclimab (BGB-A425) and Alcestobart (LBL-007) in Combination With Tislelizumab in Advanced Solid Tumors

Overall registry status Completed

Phase 1 · Phase 2

Conditions HNSCC for Phase 2 Dose Expansion, Locally Advanced or Metastatic Solid Tumors for Phase 1, Dose Escalation and Phase 2 Safety Lead-in, NSCLC for Phase 2 Dose Expansion

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov